SCHEMBL30774399

SCHEMBL30774399

COc1ccc(C(=O)N2CCc3c(-c4ccc(C#N)cc4)cncc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 4/20 0.51
▸ UCHL1 P09936 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ PTGER4 P35408 1/20 0.44
▸ PTGER2 P43116 1/20 0.44
▸ PTGDR Q13258 1/20 0.44
▸ USP30 Q70CQ3 1/20 0.43
▸ PRKAB2 O43741 1/20 0.43
▸ PRKAG1 P54619 1/20 0.43
▸ PRKAA2 P54646 1/20 0.43
▸ PRKAA1 Q13131 1/20 0.43
▸ PRKAG3 Q9UGI9 1/20 0.43
▸ PRKAG2 Q9UGJ0 1/20 0.43
▸ PRKAB1 Q9Y478 1/20 0.43
▸ TSHR P16473 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30774625 0.92 USP30 (0.49) CYP11B2UCHL1USP30CYP11B1PDCD1
SCHEMBL31635535 0.90 PDCD1 (0.44) CYP11B2UCHL1USP30CYP11B1PDCD1
SCHEMBL30774430 0.90 PDCD1 (0.44) CYP11B2UCHL1USP30CYP11B1PDCD1
SCHEMBL30774363 0.89 CYP11B2 (0.55) CYP11B2UCHL1SMN1; SMN2USP30TSHR
SCHEMBL30774532 0.89 USP30 (0.46) CYP11B2UCHL1SMN1; SMN2RAB9AUSP30
SCHEMBL33532547 0.88 SLC22A12 (0.50) CYP11B2UCHL1USP30CYP11B1PDCD1
SCHEMBL30774426 0.87 CYP11B2 (0.48) CYP11B2UCHL1RAB9AUSP30PRKAB2
SCHEMBL30774475 0.87 USP30 (0.46) CYP11B2UCHL1USP30CYP11B1PDCD1
SCHEMBL30774348 0.85 SMN1; SMN2 (0.49) CYP11B2UCHL1SMN1; SMN2RAB9AUSP30
SCHEMBL30774411 0.85 KDM1A (0.47) CYP11B2UCHL1USP30CYP11B1PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US claimed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 CYP11B2 38/4885UCHL1 1728/4885SMN1; SMN2 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback